1037754-73-6

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl 4-((R)-3-hydroxy-1-methylpropyl)piperidine-1-carboxylate is used as a key intermediate in the synthesis of pyrrolidine derivatives for the treatment of metabolic disorders. Its unique molecular structure allows for the development of therapeutic agents that can help manage and treat these conditions effectively.
Used in Drug Development for GPR119 Modulation:
tert-butyl 4-((R)-3-hydroxy-1-methylpropyl)piperidine-1-carboxylate is also used as a therapeutic modulator of GPR119 activity. GPR119 is a G-protein coupled receptor that plays a role in glucose homeostasis and insulin secretion. By modulating GPR119 activity, tert-butyl 4-((R)-3-hydroxy-1-methylpropyl)piperidine-1-carboxylate can potentially contribute to the development of novel treatments for diabetes and other related metabolic conditions.

Upstream product

• 1037754-69-0 tert-butyl 4-((R)-2-carboxy-1-methylethyl)piperidine-1-carboxylate 

Downstream Products

• 1037780-12-3 4-[(R)-3-(4-methanesulfonylphenoxy)-1-methylpropyl]piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

PIPERIDINYL GPCR AGONISTS

Compounds of formula (I):or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.

PIPERIDINYL GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.

HETEROCYCLIC GPCR AGONISTS

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.

HETEROCYCLIC GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.

PIPERIDINE GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

PIPERIDINE GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

PIPERIDINE GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

PIPERIDINE GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.